Current challenges for the pharmaceutical industry in the context of rising cardiovascular diseases

the development of the pharmaceutical market is influenced by various economic, political, social and technological factors. In Russia, economic instability, changes in legislation, as well as socio-demographic characteristics of the population have a significant impact on the market. This is especially relevant in the context of the growing incidence of cardiovascular diseases (CVD), which are becoming one of the main causes of disability and mortality among the country's adult population. Most of the adult population of Russia is at risk of developing CVDs, especially those who suffer from diabetes mellitus, obesity, smoke or abuse alcohol, as well as those who are exposed to chronic stress and lack of physical activity. Statistics confirm that in recent decades there has been a deterioration in the health of the population, which requires urgent action to improve the prevention and treatment of heart and vascular diseases. To combat cardiovascular disease, in addition to the basic treatment needed to control and stabilise patients, prevention plays a crucial role. Important aspects of prevention include timely diagnosis, healthy lifestyles, reducing consumption of unhealthy foods, regular physical activity and psycho-emotional well-being. As part of a comprehensive approach in the treatment of CVDs, the pharmaceutical market plays a key role in ensuring the availability of modern medicines, as well as the introduction of new technologies and treatment methods. In addition, effective prevention and treatment of CVDs require active co-operation between government authorities, medical institutions and pharmaceutical companies. Only coordinated efforts in the healthcare sector can lead to a significant reduction in morbidity, disability and mortality from cardiovascular diseases.

cardiovascular disease, pharmaceuticals, pharmaceutical market